These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26372321)

  • 21. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
    Steen O; Goldenberg RM
    Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
    Imprialos KP; Stavropoulos K; Stavropoulos N; Patoulias D; Petidis K; Grassos C; Dimitriadis K; Tsioufis C
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):104-113. PubMed ID: 29412121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Overview of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus.
    Miller EM
    J Fam Pract; 2017 Feb; 66(2 Suppl):S5-S12. PubMed ID: 28222460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empagliflozin for the treatment of type 2 diabetes.
    Jahagirdar V; Barnett AH
    Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Role of the Kidney in Glucose Homeostasis: Implications for SGLT-2 Inhibition in the Treatment of Type 2 Diabetes Mellitus.
    Miller EM
    J Fam Pract; 2017 Feb; 66(2 Suppl):S3-S5. PubMed ID: 28222459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse effects and safety of SGLT-2 inhibitors.
    Halimi S; Vergès B
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
    Arakaki RF
    Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ; Delanaye P
    Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
    Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
    Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
    Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
    J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
    Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
    Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.